Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Rewey Asset Management Chip Rewey | “Varex Imaging was our top 3Q25 performer, posting a return of 43.02%. Its share price recovered from its “Liberation Day” sell off as the investors recognized the tariff impact on VREX should not be as bad as feared. VREX's China business predominantly serves only China, and the market there for VREX has improved. VREX also has significant flexibility to move production globally to offset the worst impacts of tariffs. We continue to think VREX is undervalued and neglected, as analysts have not recognized the healthcare CT market recovery and the growing strength of its security screening offerings. BSD Analysis: Varex is a pure-play x-ray imaging component supplier with deep OEM relationships and a defensible position in detectors and tubes. The business is cyclical, but margins are expanding as supply-chain pressures ease and mix tilts toward higher-value digital components. Healthcare demand is sticky, and industrial NDT markets add incremental torque. Varex is not a flashy med-tech name, but its installed base gives it long-duration revenue stability. The stock trades at a discount as if growth is structurally capped — it isn't. Execution has tightened, and cash flow is improving. A quiet imaging infrastructure play with more upside than its valuation implies.” | BULL | Q3 2025 Oct 1, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
